Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-Controlled, Double-masked Phase-1 Study in Healthy Subjects Investigating the Safety and Tolerability of Laquinimod Eye Drops

Next Previous
X
Search
Trial Profile

A Placebo-Controlled, Double-masked Phase-1 Study in Healthy Subjects Investigating the Safety and Tolerability of Laquinimod Eye Drops

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Laquinimod (Primary)
  • Indications Uveitis; Wet age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors Active Biotech

    • Most Recent Events

    • 30 Jan 2023 According to Active Biotech Media Release, all data from the study is currently being analyzed, and the full study results will be reported in the first half of 2023.
    • 30 Jan 2023 Preliminary results published in the Active Biotech Media Release
    • 30 Jan 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top